Patents by Inventor Svetlana A. Dambinova

Svetlana A. Dambinova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170176459
    Abstract: Provided herein are compositions, methods and kits for determining the level of an AMPAR/KAR peptides in a subject. The methods include obtaining a biological sample from the subject and determining a level of one or more AMPAR/KAR peptides selected from the group consisting of GluR1/GluR6_7, GluR2/GluR6_7, GluR3/GluR6_7, GluR1/GluR6, GluR2/GluR7, and any combination thereof in the biological sample.
    Type: Application
    Filed: December 22, 2016
    Publication date: June 22, 2017
    Applicant: GRACE LABORATORIES, LLC
    Inventors: Svetlana Dambinova, Alexander Skoromets
  • Patent number: 8569448
    Abstract: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression. (2) ischemic conditions in the central and peripheral nervous systems, and (3) the type and cause of chronic pain.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: October 29, 2013
    Assignee: Grace Laboratories, LLC
    Inventor: Svetlana A. Dambinova
  • Publication number: 20120083586
    Abstract: The present invention relates to methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression, and (2) ischemic conditions in the central and peripheral nervous systems.
    Type: Application
    Filed: November 10, 2011
    Publication date: April 5, 2012
    Applicant: CIS BIOTECH, INC.
    Inventor: Svetlana Dambinova
  • Publication number: 20120010147
    Abstract: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression. (2) ischemic conditions in the central and peripheral nervous systems, and (3) the type and cause of chronic pain.
    Type: Application
    Filed: July 25, 2011
    Publication date: January 12, 2012
    Applicant: Grace Laboratories, LLC
    Inventor: Svetlana DAMBINOVA
  • Patent number: 8084225
    Abstract: Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and neuroimaging, and are directed to risk assessment, prognosis, diagnosis and treatment of TIA and stroke on an emergency basis in the emergency room.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: December 27, 2011
    Assignee: CIS Biotech, Inc.
    Inventor: Svetlana A. Dambinova
  • Patent number: 7820398
    Abstract: Immunosorbents, kits and compositions for diagnosing a central nervous system disorder, particularly paroxysmal cerebral discharges and epilepsy, comprising measuring the concentration of GluR1 or fragment thereof and/or GluR1 antibodies in a biological sample from a human subject. The method is particularly useful for identifying individuals that are at risk for brain related seizures and epilepsy, for distinguishing epilepsy from pseudo-epilepsy and epilepsy-like disorders, for following up after anticonvulsive treatment, and for the adjustment of adequate therapy and doses.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: October 26, 2010
    Assignee: Grace Laboratories Inc.
    Inventors: Svetlana A. Dambinova, Galina Izykenova
  • Publication number: 20100210816
    Abstract: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression, and (2) ischemic conditions in the central and peripheral nervous systems. Further provides are therapeutic strategies and interventions for the treatment and prevention of stroke, cardiovascular disease, and ischemic lesions in the brain and peripheral nervous system, and pulmonary disorders based on the results of such diagnoses.
    Type: Application
    Filed: December 12, 2007
    Publication date: August 19, 2010
    Inventor: Svetlana Dambinova
  • Publication number: 20100173789
    Abstract: Methods are provided for predicting the occurrence of adverse neurological events from surgery. Such adverse events include, for example, stroke, delirium and transient ischemic attack (TIA). The methods are based on the discovery that levels of circulating cerebral NMDA receptor peptides and antibodies can be used to identify patients who are likely to suffer from an adverse neurological event. Also provided are diagnostic procedures for practicing the predictive methods of the current invention, and interventional strategies for reducing the risk of adverse neurological events from surgery.
    Type: Application
    Filed: January 7, 2010
    Publication date: July 8, 2010
    Applicant: CIS Biotech, Inc.
    Inventor: Svetlana A. Dambinova
  • Patent number: 7658911
    Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: February 9, 2010
    Assignee: CIS Biotech, Inc.
    Inventor: Svetlana A. Dambinova
  • Patent number: 7622114
    Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 24, 2009
    Assignee: CIS Biotech, Inc.
    Inventor: Svetlana A. Dambinova
  • Patent number: 7622100
    Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: November 24, 2009
    Assignee: CIS Biotech, Inc.
    Inventor: Svetlana A. Dambinova
  • Publication number: 20090275736
    Abstract: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression, (2) ischemic conditions in the central and peripheral nervous systems, and (3) the type and cause of chronic pain.
    Type: Application
    Filed: December 12, 2007
    Publication date: November 5, 2009
    Inventor: Svetlana Dambinova
  • Publication number: 20090181006
    Abstract: Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and neuroimaging, and are directed to risk assessment, prognosis, diagnosis and treatment of TIA and stroke on an emergency basis in the emergency room.
    Type: Application
    Filed: June 13, 2006
    Publication date: July 16, 2009
    Inventor: Svetlana A. Dambinova
  • Publication number: 20080206793
    Abstract: Methods are provided for predicting the occurrence of adverse neurological events from surgery. Such adverse events include, for example, stroke, delirium and transient ischemic attach (TIA). The methods are based on the discovery that levels of circulating cerebral NMDA receptor peptides and antibodies can be used to identify patients who are likely to suffer from an adverse neurological event. Also provided are diagnostic procedures for practicing the predictive methods of the current invention, and interventional strategies for reducing the risk of adverse neurological events from surgery (FIG. 1).
    Type: Application
    Filed: January 24, 2006
    Publication date: August 28, 2008
    Inventor: Svetlana A. Dambinova
  • Publication number: 20060281135
    Abstract: Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and neuroimaging, and are directed to risk assessment, prognosis, diagnosis and treatment of TIA and stroke on an emergency basis in the emergency room.
    Type: Application
    Filed: June 13, 2006
    Publication date: December 14, 2006
    Inventor: Svetlana Dambinova
  • Publication number: 20060257943
    Abstract: Methods are provided for predicting the occurrence of adverse neurological events from surgery. Such adverse events include, for example, stroke, delirium and transient ischemic attack (TIA). The methods are based on the discovery that levels of circulating cerebral NMDA receptor peptides and antibodies can be used to identify patients who are likely to suffer from an adverse neurological event. Also provided are diagnostic procedures for practicing the predictive methods of the current invention, and interventional strategies for reducing the risk of adverse neurological events from surgery.
    Type: Application
    Filed: January 23, 2006
    Publication date: November 16, 2006
    Inventor: Svetlana Dambinova
  • Publication number: 20060172341
    Abstract: A methods, kits and, compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
    Type: Application
    Filed: January 25, 2006
    Publication date: August 3, 2006
    Inventor: Svetlana Dambinova
  • Publication number: 20060172342
    Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
    Type: Application
    Filed: January 25, 2006
    Publication date: August 3, 2006
    Inventor: Svetlana Dambinova
  • Publication number: 20060024749
    Abstract: A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
    Type: Application
    Filed: March 9, 2005
    Publication date: February 2, 2006
    Inventor: Svetlana Dambinova
  • Publication number: 20050181466
    Abstract: Immunosorbents, kits and compositions for diagnosing a central nervous system disorder, particularly paroxysmal cerebral discharges and epilepsy, comprising measuring the concentration of GluR1 or fragment thereof and/or GluR1 antibodies in a biological sample from a human subject. The method is particularly useful for identifying individuals that are at risk for brain related seizures and epilepsy, for distinguishing epilepsy from pseudo-epilepsy and epilepsy-like disorders, for following up after anticonvulsive treatment, and for the adjustment of adequate therapy and doses.
    Type: Application
    Filed: November 8, 2004
    Publication date: August 18, 2005
    Applicant: Grace Laboratories, Inc.
    Inventors: Svetlana Dambinova, Galina Izykenova